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Abstract Interleukin-6 mediates its pleiotropic effects by 
interacting with its membrane bound receptor (gp80) or the 
soluble counterpart gp54, resulting in activation of a complex 
that includes the transducer protein gpl30. We have generated a 
polyclonal antibody against the rat soluble IL-6 receptor (anti-
rat sIL-6R) in rabbits. By Western blot analysis we show that 
purified anti-rat sIL-6R IgG antibody reacts specifically with 
recombinant rat sIL-6R generated from E. coli, baculovirus or 
adenovirus expression systems. Anti-rat sIL-6R inhibited IL-6-
induced acute phase protein synthesis in rat (H35) but not human 
(HepG2) hepatoma cells, and did not affect stimulation of those 
cells by Oncostatin-M. Conversely, on the mouse hybridoma B9 
cell line, IgG anti-rat sIL-6R showed a dose-dependent stimula-
tion of proliferation. Fab fragments of this antibody did not 
stimulate, but abrogated IL-6-mediated hepatoma cell stimula-
tion and B9 cell proliferation. Gel shift analysis of ST AT nuclear 
factors showed activation of ST AT DNA binding in nuclei of B9 
cells treated with IgG anti-rat sIL-6R, whereas in H35, NIH-
3T3 and M l cells, only IL-6 could trigger a similar STAT 
activation. Our data suggest that mechanisms of IL-6 receptor 
activation and signalling in mouse B9 hybridoma cells show 
subtle but important differences from other IL-6-responsive cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Interleukin-6 (IL-6) belongs to the family of hematopoietic 
cytokines that includes IL-6, Interleukin-11 (IL-11), Oncosta-
tin-M (OSM), leukemia inhibitory factor (LIF), ciliary neuro-
trophic factor (CNTF) and cardiotrophin-1 (CT-1) (for review 
see [1,2]). These cytokines share various activities since they 
act through receptor complexes that include the common sig-
nal transducer glycoprotein, gpl30. The IL-6 receptor com-
plex includes the unique ligand-binding IL-6 receptor chain 
(IL-6R). IL-6 interacts first with membrane bound IL-6R or 
its soluble counterpart (sIL-6R), and this primary complex 
interacts with gpl30 [3,4]. IL-6-induced dimerization of 
gpl30 activates Janus kinase (Jak) family of tyrosine kinases, 
depending upon the cell types (for review see [5,6]), which 
phosphorylate several tyrosine residues along gpl30 . This al-
lows recruitment, through the SH2 domain, of members of the 
signal transducers and activators of transcription (STAT) 
family, namely STAT-1 and STAT-3, which also become 
phosphorylated by the Jak bound to gpl30 [7,8]. Activated 
STAT proteins then form hetero- and homo-dimers and trans-
locate to the nucleus where they behave as transcriptional 
factors and bind to specific promoter sequences (such as 
*Corresponding author. Fax: (1) (905) 577-0198. 
A P R - R E and NF-IL-6RE) upstream of IL-6-induced genes 
such as acute phase proteins in the liver [9,10]. 
The presence of the soluble IL-6 receptor (extracellular do-
main) has been shown to enhance responses to IL-6 in hep-
atocytes [11,12] and in other cells that possess gpl30 but lack 
the membrane IL-6R form [13-16]. This is in contrast to the 
action of other soluble receptors which inhibit ligand function 
[17,18]. In order to specifically inhibit biological responses 
mediated by the IL-6 receptor in rat cells in vitro and in 
vivo, we generated specific antibodies to the rat IL-6 soluble 
receptor. In this paper we show that purified polyclonal anti-
bodies against rat sIL-6R can specifically inhibit IL-6-induced 
acute phase protein stimulation in hepatocytes. The antibody 
also inhibits IL-6-induced STAT activation in rat hepatocytes 
and in other IL-6-responsive cells (mouse M l and NIH-3T3 
cells). In contrast, the antibodies possess a potent agonistic 
activity on proliferation of the mouse hybridoma B9 cell line, 
and can activate STAT proteins in B9 cells. Purified specific 
F a b fragments on the other hand inhibit B9 cell proliferation 
and associated STAT activation. These studies have raised 
several issues regarding qualitative differences between B9 
cells and other IL-6-responsive cells within these model sys-
tems. 
2. Material and methods 
2.1. Acute phase protein production and B9 cell proliferation 
The effects of cytokines or antibody on human HepG2 and rat H35 
hepatoma cell production of acute phase proteins was determined on 
confluent monolayer cells in 24 well cluster plate containing 300 JJ.1 of 
media. Cells were stimulated for 48 h, media was removed and the 
concentrations of acute phase proteins were analyzed by rocket im-
munoelectrophoresis using agarose containing specific antibody as 
previously described [19]. The B9 hybridoma proliferation assay was 
performed as previously described and analyzed using a colorimetric 
development [20,21]. 
2.2. Antibody and cytokines 
Specific antibodies against the rat soluble IL-6 receptor were gen-
erated in rabbits immunized with a replication deficient recombinant 
adenovirus encoding the soluble form of the rat IL-6R as previously 
described (Thibault et al., manuscript submitted). Fab fragments were 
generated using immobilized papain (Pierce Biochemicals) according 
to manufacturer's instructions. Fc fragments were removed by chro-
matography on a protein A column (Pharmacia). Rat IL-6 was pro-
duced in E. coli and affinity purified on a Ni chelate column as pre-
viously described [22]. Human IL-6 and OSM are generous gifts from 
Dr. M. Widmer (Immunex Corp., Seattle, WA) and Dr. P. Wallace 
(Bristol-Myers Squibb Research Institute, Seattle, WA), respectively. 
2.3. Gel shift assay 
Cells were treated with cytokines and/or antibody as indicated for 
15 min. Nuclear extracts were prepared as described previously [23]. 
Oligo nucleotide probes corresponding to the high affinity sis-induci-
ble element SIE [24] were annealed, labeled and purified (sequences 
are: 5'-GTCGACATTTCCCGTAAATC-3' and 5'-TCGACGATT-
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TACGGGAAATG-3'). For the assay, nuclear extracts were incu-
bated for 15 min on ice with 2 ug of poly (dl.dC) and 5 ug of calf 
thymus DNA in binding buffer as described. Probe (2 X 105 cpm) was 
added and the reaction was incubated 20 min at r.t. Loading buffer 
was added, and samples were electrophoresed (5% polyacrylamide) at 
95 V for 4 h. The gels were then dried before autoradiography. 
120 -, 
2.4. Western blot 
Proteins were run 
ing conditions. The 
brane (Immobilon). 
Tween 1% PBS, the 
the same solution 
antibody (goat anti-
chemiluminescence 
turers specification 
3. Results 
on a 7.5 or 10% polyacrylamide gel under reduc-
gels were transferred onto a nitrocellulose mem-
After blocking for 1 h into 5% blotto, 1% BSA, 
antibodies were added to a dilution of 1/5 000 in 
Development was carried out with a secondary 
rabbit, SIGMA) labeled with peroxidase and a 
system (Dupont-NEN) according to manufac-
3.1. Antibodies raised against rat sIL-6R react specifically with 
recombinant rat IL-6R produced in E. coli, insect cells or 
mammalian cells 
Specific antibodies were raised in rabbits by vaccination 
with a recombinant adenovirus expressing the extracellular 
domain of rat IL-6R (Thibault et al., manuscript submitted) 
and boosting with baculovirus expressed purified recombinant 
sIL-6R protein. A Western blot using this antibody shows 
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Fig. 2. Specific IgG or Fab inhibit IL-6-induced CPI synthesis from 
H35 cells. H35 cells were stimulated for 2 days with 2 ug/ml of rat 
IL-6, in the presence of increasing amounts of anti-rat sIL-6R (filled 
box) or anti-rat IL-6 (empty box) IgG and supernatants were ana-
lyzed for CPI content. Results are expressed as the mean of 3 differ-
ent experiments with standard error; B: H35 cells were stimulated 
with 50 ng/ml of human OSM, 100 ng/ml of human IL-6 or 500 ng/ 
ml of rat IL-6 in presence of control IgG (50 ug/ml, empty box), 
anti-rat sIL-6R specific IgG (32 ug/ml, filled box) or anti-rat sIL-6R 
specific Fab fragments (50 ug/ml, dotted box). CPI concentration 
was determined after a 2 day stimulation. Results are expressed as 
the mean of 3 different experiments with standard error. 
Fig. 1. Specific IgG recognize different preparations of rsIL-6R. Pu-
rified protein or infected cell supernatants (24 h) were run on a 
polyacrylamide gel, transferred onto a PVDF membrane, analyzed 
by Western blot with specific purified IgG anti-rat sIL-6R and re-
vealed with a chemiluminescent detection assay. Samples were: puri-
fied recombinant rat sIL-6R expressed in E. coli (lane 1) or insect 
cells (lane 2); recombinant adenovirus, expressing rat sIL-6R 
(Ad5.rsIL-6R (lanes 3 and 5), or control virus Ad5.LacZ (lanes 4 
and 6)) infected cells supernatants (H35 cells (lanes 3 and 4) or 
HepG2 cells (lanes 5 and 6)). 
specific reactivity with rat sIL-6 expressed as a 33 k D a protein 
from E. coli (lane 1), with 50 k D a rat sIL-6R expressed in 
baculovirus [19] (lane 2) and with a 55 k D a protein expressed 
from adenovirus vector in infected human HepG2 (lane 3) or 
rat H35 hepatoma cells (lane 5) (Fig. 1). Lanes 4 and 6 show 
supernatants of HepG2 or H35 cell supernatants infected with 
control virus and indicate no reactivity. The difference in size 
of materials detected is likely due to the lack of glycosylation 
in prokaryotic cells and different glycosylation patterns be-
tween insect and mammalian cells. The antibody we used 
had been purified (IgG fraction) and has been termed anti-
rat sIL-6R. 
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Fig. 3. rsIL-6R-specific IgG induce B9 cell proliferation. B9 cells 
were incubated for 72 h in presence of increasing concentrations of 
rat IL-6 (U/ml; open square) or rat sIL-6R (u.g/ml; closed circle) 
specific IgG. Proliferation was measured by an MTT assay and read 
on a spectrophotometer at 570 nm. A representative experiment 
done in triplicate is shown, results are expressed as mean ± standard 
error. 
3.2. Anti-rat sIL-6R inhibits IL-6-induced acute phase response 
but does not modify OSM response 
To test the ability of the antibody to inhibit IL-6-induced 
cell responses, anti-rat sIL-6R (or purified Fab fragments or 
preimmune control IgG) was assessed for effects on cytokine-
induced acute phase protein response of rat H35 and human 
HepG2 hepatoma cells. Increasing concentrations of anti-rat 
sIL-6R specific IgG inhibited IL-6-induced ocl-cysteine pro-
tease inhibitor (CPI, a typical acute phase protein) production 
from H35 cells in a dose-dependent manner (Fig. 2A). At low 
concentration of anti-rat sIL-6R (7.8 Hg/ml), we could inhibit 
more than 20% of CPI production induced with 2 ug/ml rat 
IL-6 and at 63 itg/ml, we obtained a 61% inhibition, similar to 
that seen with an equivalent amount of a neutralizing anti-
body against IL-6 ligand. 63 ug/ml anti-rat sIL-6R also in-
hibited 85% of CPI secretion by H35 cells that were stimu-
lated with 100ng/ml of human IL-6. Neither control IgG nor 
specific anti-rat sIL-6R modified the spontaneous synthesis of 
acute phase proteins, and control IgG had no influence on IL-
6-induced CPI production (not shown). 
In order to better characterize the specificity of this effect, 
we analyzed CPI production in H35 cells that were stimulated 
with 50 ng/ml of OSM in the presence of specific or control 
IgG (Fig. 2B). OSM induces CPI in these cells but does not 
interact with the IL-6R. Use of inhibitory concentrations of 
specific IgG anti-rat sIL-6R (63 ug/ml) did not modify OSM-
induced CPI production, suggesting the antibody was acting 
at the IL-6R gp80 level and not on the gpl30 transducer 
protein. In order to rule out a non-specific effect of IgG mol-
ecules at the cell surface, we generated Fab fragments of the 
anti-rat sIL-6R by papain cleavage. Used at similar concen-
trations to intact IgG, purified Fab fragments (24 itg/ml) 
showed a similar inhibitory effect on rat IL-6-induced acute 
phase protein production (Fig. 2B). Experiments carried out 
on human HepG2 cells did not show inhibitory action of the 
anti-rat sIL-6R on human IL-6-induced responses (not 
shown). 
3.3. Anti-rat sIL-6R specific IgG can induce proliferation of B9 
cells, whereas Fab fragments inhibit 
Proliferation of the B9 hybridoma cell line is widely used as 
a sensitive assay of IL-6 biological activity. Surprisingly, and 
contrary to what we observed on rat hepatoma cells, specific 
IgG anti-rat sIL-6R alone showed a strong agonistic effect 
(Fig. 3). As low as 1 ng of specific IgG could induce B9 cell 
growth with maximum proliferation induced with 300 ng. The 
dose response was roughly similar in profile to the IL-6 re-
sponse curve, and had similar maximum values. By compar-
ison, 20 ng of specific IgG could induce proliferation equal to 
that seen with 1 U of IL-6. In contrast to specific IGg anti-rat 
sIL-6R, purified Fab fragments had no stimulatory effect on 
proliferation. When B9 cells were incubated in presence of 2 U 
of IL-6, increasing concentration of Fab fragments markedly 
inhibited IL-6-induced proliferation (Fig. 4), similar to inhib-
itory effects of Fab fragments on CPI production by H35 cells 
(Fig. 2B). Thus monovalent specific antibody was inhibitory, 
but bivalent cross-linking antibody was stimulatory in B9 
cells. 
3.4. Anti-rat sIL-6R induces ST AT activation in B9 cells, but 
not other IL-6-responsive cells 
To further explore the mechanism by which anti-rat sIL-6R 
activates B9 cells, we examined the activation of STAT pro-
teins in nuclear extracts of stimulated cells. IL-6 stimulation 
of B9 cells induced a strong activation of STAT-binding ac-
tivity as shown by gel shift assay (Fig. 5) as has been estab-
lished previously. Lane 4 (human IL-6, 400 U/ml) and 5, 6, 7 
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Fig. 4. rsIL-6R-specific Fab fragments prevent IL-6-induced B9 cell 
proliferation. B9 cells were incubated for 72 h in the presence of 2 U 
of rat IL-6 in 96 well plates with addition of 50 |i.g/ml control IgG 
(CTRL) or rat sIL-6R-specific Fab fragments at increasing concen-
trations. Results are expressed as percentage of proliferation as 
compared to cells incubated with similar concentrations of control 
IgG. A representative experiment is shown. 
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4. Discussion 
Fig. 5. STAT activation in B9 cells. Cells were untreated (lane 1), 
treated with IgG anti-rat sIL-6R (63 u,g/ml, lane 2 or 126 |xg/ml, 
lane 3), hIL-6 (400 U/ml, lane 4), rIL-6 (16, 1 or 0.25 U/ml, lanes 
5, 6 and 7 respectively) or a combination (lane 8) of rIL-6 (16 U/ 
ml) and Fab anti sIL-6R (30 ug/ml). Gel shift analysis was per-
formed as in Section 2 with SIE probe and nuclear extracts. The gel 
shifts corresponding to STAT activated complexes are indicated. 
(16, 1, 0.25 U/ml respectively of rat IL-6) show a dose-de-
pendent induction with detection of specific bands for STAT 
dimers. This probe detects binding of STAT-1 and STAT-3 
homo- and hetero-dimers which migrate closely together (Fig. 
5) but can be seen as separate bands when run longer on gels 
(Fig. 6). These bands were supershifted by anti-STAT anti-
bodies (not shown). In the presence of specific IgG anti-rat 
sIL-6R alone (lanes 2 and 3, 63 and 126 ug/ml of IgG respec-
tively), STAT activation was strongly induced in B9 cell ex-
tracts, to an extent similar to that seen with high concentra-
tions of IL-6 (Fig. 5). In contrast, stimulation of B9 cells with 
IL-6 in the presence of Fab fragments of anti-rat sIL-6R 
dramatically reduced IL-6-induced STAT activation (compare 
lane 5 versus 8). The same amount of Fab fragments inhibited 
proliferation by approximately 80%. 
In H35 cells (Fig. 6) IL-6 induced high amounts of STAT 
binding to the SIE probe at 15 min after stimulation. Treat-
ment with the specific antibody to sIL-6R alone did not alter 
levels of signal, however in combination with IL-6, the anti-
body dramatically inhibited STAT activation as did the Fab 
fragments. We also tested the action of the antibody on other 
IL-6-responsive mouse cell lines, including the myeloid leuke-
mia cell line Ml , and an embryonic fibroblast cell line Nl H-
3T3. In both cell types, IL-6-induced marked STAT activa-
tion, and inclusion of anti-rat sIL-6R IgG inhibited the IL-6 
effect. The antibody alone was again without detectable effects 
on STAT. In contrast, shown in the top panel of Fig. 6, a 
parallel experiment with B9 cells shows STAT activation by 
IgG anti-rat sIL-6R alone, and augmentation of STAT bind-
ing with IL-6 and antibody treatment. 
We have generated antibodies against the rat soluble IL-6 
receptor, which specifically recognize the receptor as demon-
strated by its detection of a single band on Western blot when 
used to probe recombinant sIL-6R protein from various ex-
pression systems (Fig. 1). Our experiments on rat H35 hepa-
toma cells clearly demonstrate the ability of specific IgG di-
rected against rat sIL-6R to block IL-6-induced acute phase 
protein production (Fig. 2). This was specific for IL-6R-medi-
ated events since OSM stimulation of cells was not affected. 
OSM has been recently shown to act through at least two 
different receptor complexes, the LIF receptor (LIFR) and 
the specific Oncostatin-M receptor (OSMR) [25,26], both of 
which require gpl30 for signalling. The antibody did not af-
fect HepG2 cells, consistent with low homology between rat 
and human receptors [27]. Non-specific effects due to Fc por-
tion of IgG molecules were ruled out on the basis of Fab 
fragment experiments that confirmed reactivity with specific 
epitomes of gp80 (Fig. 2). 
As it is now well established, IL-6 by interacting with its 
specific receptor induces B9 cell proliferation. Receptor-ligand 
interaction induces STAT activation, the role of which in 
proliferation is not yet fully delineated. Alternatively, other 
pathways such as MAP kinases, triggered after Jak phosphor-
ylation [28], may be involved in B9 cell proliferation. Contrary 
to expectations, our results showed that specific IgG antibod-
ies directed against gp80-induced STAT activation and a dra-
matic proliferation similar to that induced by IL-6 (Fig. 3), 
whereas Fab fragments were inhibitory (Figs. 3-6). Recent 
studies by others have shown that cross-linking of human 
gpl30 with a specific antibody can induce Jak kinase and 
Fig. 6. comparison of STAT activation in B9, H35, 3T3-NIH and 
Ml cells. Cells were untreated (lane 1), treated with rIL-6, 16 U/ml 
(lane 2) anti-rat sIL-6R, 63 ug/ml (lane 3) or the combination (lane 
4) as indicated. Gel shift analysis was performed as in Section 2 
with SIE probe and nuclear extracts. The gel shifts corresponding 
to STAT activated complexes are indicated. 
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biologic responses in HepG2 cells and hematopoietic cells [29]. 
We suggest that in B9 cells treated with specific IgG anti-rat 
sIL-6R, two molecules of gp80 are cross-linked sufficiently to 
induce activation of Jak kinase(s) and subsequent ST AT acti-
vation and a proliferation signal. Fab fragments, on the other 
hand, exhibit monovalent reactivity with antigen, cannot in-
duce dimerization and therefore block the ligand site and any 
IL-6-induced effects. 
Interestingly, this apparently does not occur in other IL-6-
responsive cells including rat H35 hepatoma cells, mouse 
NIH-3T3 fibroblasts and mouse Ml cells, where IgG anti-
rat sIL-6R inhibited signalling events, as measured by ST AT 
activation (Fig. 6). Since IgG anti-rat sIL-6R reacts specifi-
cally with gp80 and not with gpl30, our experiments imply 
either that gp80, at least on B9 cells, are pre-associated with 
gpl30 free of IL-6 or with a residual amount of ligand already 
bound to it. We and others have previously noted the possi-
bility that B9 cells can secrete low amounts of IL-6 [12,16,19]. 
This could explain the proliferation activity of recombmant 
sIL-6R by itself without addition of exogenous IL-6. This sIL-
6R agonist activity has not been reported for other cell lines 
and it is therefore very likely that the B9 cell IL-6R/gpl30 
complex differs slightly from that described for other cell lines. 
Alternatively, binding of specific antibody to gp80 may induce 
a conformational change allowing for the binding of gp80 
with gpl30. Others have reported agonistic activities of recep-
tor domain (WSEWS) specific monoclonal antibodies on 
HepG2 cells [30], also suggesting cross-linking of receptor 
components can induce signals. In addition, activation of sev-
eral Jak kinases in the IL-6 signalling pathway have already 
been demonstrated by several authors [7,31-33]. Thus the dif-
ference between B9 cells and the other cells tested could be 
due to relative amounts of separate Jak kinase family mem-
bers which differ in response to cross-linking of gp80. Further 
experimentation is needed to determine the exact nature of 
these differences in IL-6 signalling. 
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